PartoSure includes a noninvasive strip test that detects placental alpha microglobulin in patients and is already being used in 35 countries in Europe, the Middle East, Asia, and Latin America.

The DOJ alleged Biotheranosics promoted and performed its Breast Cancer Index test for  patients who had not been in remission for five years and who had not been taking tamoxifen.

The firm aims to offer a clinical service next year for predicting immunotherapy response and adverse immune reactions.

The five-year-old firm recently completed a clinical trial of the real-time PCR-based test, called ProALL-BM, on patients from a European National Registry Study.

The FDA approved its use with tissue or plasma biopsies, giving clinicians a non-invasive option to conduct a test that provides results in a day.

Pivoting from a technology that it deemed wasn't robust enough, Confer Health is now designing a platform to enable broad-scale testing at home.  

The DOJ alleged Biotheranosics promoted and performed its Breast Cancer Index test for  patients who had not been in remission for five years and who had not been taking tamoxifen.